738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors

• Daniel J Olson,
• Ecaterina Dumbrava,
• Benjamin Schlechter,
• Maria Apostolopoulou,
• Kara Moss,
• Deyaa Adib,
• Sam Saibil,
• Martin Gutierez,
• Syma Iqbal,
• Davendra Sohal

Affiliations

Daniel J Olson

1University of Chicago, Chicago, IL, USA

Ecaterina Dumbrava

2The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Benjamin Schlechter

9Dana-Farber Cancer Institute, Boston, MA, USA

Maria Apostolopoulou

7Triumvira Immunologics Inc., Falmouth, MA, USA

Kara Moss

8Triumvira Immunologics, Austin, TX, USA

Deyaa Adib

8Triumvira Immunologics, Austin, TX, USA

Sam Saibil

3University Health Network Princess Margaret, Toronto, ON, Canada

Martin Gutierez

4Hackensack University Medical Center, Hackensack, NJ, USA

Syma Iqbal

5Usc Norris Comprehensive Cancer Ctr Div Onc, Los Angeles, CA, USA

Davendra Sohal

6University of Cincinnati Cancer Center, Cincinnati, OH, USA